The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
Open accessAbstract
In order to test the suggestion that antipsychotic drugs act by blocking dopamine receptors in the brain, the direct effects of such neuroleptic drugs were tested on the stereospecific binding of [3H]dopamine and of [3H]haloperidol to rat brain striata and their subfractions. The stereospecific component of binding was defined as that amount of [3h]dopamine or [3H]haloperidol bound in the presence of (-)-butaclamol (an inactive drug) minus that bound in the presence of (+)-butaclamol (a potent neuroleptic drug); 100 nM butaclamol was used for the [3H]haloperidol assay, while 1 muM butaclamol was used for the [3H]dopamine assay. Various antipsychotic drugs inhibited this stereospecific component in both the dopamine and haloperidol assays. These inhibitory potencies correlated with the clinical doses used for controlling schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Opiate Receptor: Demonstration in Nervous Tissue
Pert, C. B., & Snyder, S. H. (1973) · Science · doi:10.1126/science.179.4077.1011 · Cited by 2,388
The Membrane Actions of Anesthetics and Tranquilizers
Seeman, P. (1972) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06931-5 · Cited by 2,246
Self-citationCarlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148
DOPAMINE (3-HYDROXYTYRAMINE) AND BRAIN FUNCTION
HORNYKIEWICZ, O. (1966) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)07154-6 · Cited by 1,442
DOPAMINERGIC NEURONS: EFFECT OF ANTIPSYCHOTIC DRUGS AND AMPHETAMINE ON SINGLE CELL ACTIVITY
BUNNEY, B. S., WALTERS, J. R., ROTH, R. H., & AGHAJANIAN, G. K. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29539-8 · Cited by 1,283
Seeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869
Self-citationSnyder, S. H., Banerjee, S. P., Yamamura, H. I., & Greenberg, D. (1974) · Science · doi:10.1126/science.184.4143.1243 · Cited by 834
Cuatrecasas, P. (1974) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.43.070174.001125 · Cited by 639
Iversen, L. L. (1975) · Science · doi:10.1126/science.2976 · Cited by 527
The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.
van Rossum, J. M. (1966) · PubMed · Cited by 510
Cited by
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Self-citationDopamine: Functions, Signaling, and Association with Neurological Diseases
Klein, M. O., Battagello, D. S., Cardoso, A. R., Hauser, D. N., Bittencourt, J. C., & Correa, R. G. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0632-3 · Cited by 1,073
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Antischizophrenic Drugs: Chronic Treatment Elevates Dopamine Receptor Binding in Brain
Burt, D. R., Creese, I., & Snyder, S. H. (1977) · Science · doi:10.1126/science.847477 · Cited by 1,024
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Self-citationThe Dopamine Hypothesis of Schizophrenia: A Review*
Meltzer, H. Y., & Stahl, S. M. (1976) · Schizophrenia Bulletin · doi:10.1093/schbul/2.1.19 · Cited by 883
Dopamine receptors and the dopamine hypothesis of schizophrenia
Seeman, P. (1987) · Synapse · doi:10.1002/syn.890010203 · Cited by 880
Self-citationSerotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Dopamine Receptor Binding Enhancement Accompanies Lesion-Induced Behavioral Supersensitivity
Creese, I., Burt, D. R., & Snyder, S. H. (1977) · Science · doi:10.1126/science.877576 · Cited by 712
Half a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638
Dopamine D4 receptors elevated in schizophrenia
Seeman, P., Guan, H.-C., & Van Tol, H. H. M. (1993) · Nature · doi:10.1038/365441a0 · Cited by 628
Self-citationSerotonergic component of neuroleptic receptors
LEYSEN, J. E., NIEMEGEERS, C. J. E., TOLLENAERE, J. P., & LADURON, P. M. (1978) · Nature · doi:10.1038/272168a0 · Cited by 623
Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Dopamine receptors and brain function
Jaber, M., Robinson, S. W., Missale, C., & Caron, M. G. (1996) · Neuropharmacology · doi:10.1016/s0028-3908(96)00100-1 · Cited by 570
Phillipson, O. T. (1979) · Journal of Comparative Neurology · doi:10.1002/cne.901870108 · Cited by 553
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.12.1518 · Cited by 541
Dopamine: 50 years in perspective
Iversen, S. D., & Iversen, L. L. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.002 · Cited by 518
Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia
Meyer, U., Feldon, J., Schedlowski, M., & Yee, B. K. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.10.012 · Cited by 494
Genetic insights into the neurodevelopmental origins of schizophrenia
Birnbaum, R., & Weinberger, D. R. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.125 · Cited by 494
A Possible Role for the Striatum in the Pathogenesis of the Cognitive Symptoms of Schizophrenia
Simpson, E. H., Kellendonk, C., & Kandel, E. (2010) · Neuron · doi:10.1016/j.neuron.2010.02.014 · Cited by 478
Giros, B., el Mestikawy, S., Godinot, N., Zheng, K., Han, H., Yang-Feng, T., & Caron, M. G. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08925-4 · Cited by 477
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs
Marsden, C. D., & Jenner, P. (1980) · Psychological Medicine · doi:10.1017/s003329170003960x · Cited by 449
Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia
Mirnics, K., Middleton, F. A., Stanwood, G. D., Lewis, D. A., & Levitt, P. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000866 · Cited by 446
Receptor basis for dopaminergic supersensitivity in Parkinson's disease
LEE, T., SEEMAN, P., RAJPUT, A., FARLEY, I. J., & HORNYKIEWICZ, O. (1978) · Nature · doi:10.1038/273059a0 · Cited by 446
Self-citationThe dopamine D4 receptor: one decade of research
Oak, J. N., Oldenhof, J., & Van Tol, H. H. M. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00562-8 · Cited by 419
Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum
SCHWARCZ, R., CREESE, I., COYLE, J. T., & SNYDER, S. H. (1978) · Nature · doi:10.1038/271766a0 · Cited by 400
Kapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390
The Classification of Dopamine Receptors: Relationship to Radioligand Binding
Creese, I., Sibley, D. R., Hamblin, M. W., & Leff, S. E. (1983) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.06.030183.000355 · Cited by 389
Caron, M. G., Beaulieu, M., Raymond, V., Gagné, B., Drouin, J., Lefkowitz, R. J., & Labrie, F. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38065-1 · Cited by 383
Dopamine supersensitivity correlates with D2Highstates, implying many paths to psychosis
Seeman, P., Weinshenker, D., Quirion, R., Srivastava, L. K., Bhardwaj, S. K., Grandy, D. K., Premont, R. T., Sotnikova, T. D., Boksa, P., El-Ghundi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409766102 · Cited by 352
Self-citationHippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia
Lodge, D. J., & Grace, A. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.05.001 · Cited by 349
Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review
Stone, J. M., Morrison, P. D., & Pilowsky, L. S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073126 · Cited by 348
Psychosis pathways converge via D2High dopamine receptors
Seeman, P., Schwarz, J., Chen, J.-F., Szechtman, H., Perreault, M., McKnight, G. S., Roder, J. C., Quirion, R., Boksa, P., Srivastava, L. K., et al. (2006) · Synapse · doi:10.1002/syn.20303 · Cited by 330
Self-citationTargeting the dopamine D2receptor in schizophrenia
Seeman, P. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.4.515 · Cited by 302
Self-citationBiochemical demonstration of dopaminergic receptors in rat and human brain using [3H]spiroperidol
Fields, J. Z., Reisine, T. D., & Yamamura, H. I. (1977) · Brain Research · doi:10.1016/0006-8993(77)90084-1 · Cited by 296
The physiology and pharmacology of mammalian basal ganglia
Dray, A. (1980) · Progress in Neurobiology · doi:10.1016/0301-0082(80)90017-9 · Cited by 293
Schizophrenia: More dopamine, more D 2 receptors
Seeman, P., & Kapur, S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.7673 · Cited by 279
Self-citationDrug and Neurotransmitter Receptors in the Brain
Snyder, S. H. (1984) · Science · doi:10.1126/science.6322304 · Cited by 273
Dopaminergic supersensitivity after neuroleptics: time-course and specificity
Muller, P., & Seeman, P. (1978) · Psychopharmacology · doi:10.1007/bf00429171 · Cited by 271
“Soon after the development of the 3H-haloperidol assay method for neuroleptic/dopamine receptors (Seeman et al., 1975; Burt et at., 1975), Muller and Seeman reported that these receptors increased after long-term neuroleptic treatment (Muller and Seeman,1976; Burt et al.”
BackgroundSelf-citationNorepinephrine in Chronic Paranoid Schizophrenia: Above-Normal Levels in Limbic Forebrain
Farley, I. J., Price, K. S., McCullough, E., Deck, J. H. N., Hordynski, W., & Hornykiewicz, O. (1978) · Science · doi:10.1126/science.644310 · Cited by 269
Mechanisms of action of atypical antipsychotic drugs
Deutch, A. Y., Moghaddam, B., Innis, R. B., Krystal, J. H., Aghajanian, G. K., Bunney, B. S., & Charney, D. S. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90030-u · Cited by 253
Dopamine hypothesis of schizophrenia: Making sense of it all
Toda, M., & Abi-Dargham, A. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0041-7 · Cited by 235
“Furthermore, clinical doses of antipsychotic drugs blocked DA D 2 receptors [ 3 ,4], whereas DA-enhancing drugs were found to be psychotogenic (for review, see [5,6]).”
BackgroundAll Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors
Seeman, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00162.x · Cited by 228
“For the first time, this work provided direct evidence that all antipsychotics selectively blocked dopamine receptors with clinical potencies that correlated with their affinity for a dopamine receptor in vitro [13,14].”
BackgroundSelf-citationFifty years chlorpromazine: a historical perspective
Ban, T. A. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a922 · Cited by 227
Dopamine and psychosis: Theory, pathomechanisms and intermediate phenotypes
Tost, H., Alam, T., & Meyer-Lindenberg, A. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.06.005 · Cited by 160
Ullrich (2018) · doi:10.1038/mp.2017.188 · Cited by 145
Healy-Stoffel, M., & Levant, B. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666180412153612 · Cited by 133
“Of note, all clinically effective antipsychotic drugs are antagonists at the D2 dopamine receptor, and their affinity for the D2 receptor correlates with their clinical potency [145].”
BackgroundMillan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Valenti, O., Cifelli, P., Gill, K. M., & Grace, A. A. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2808-11.2011 · Cited by 124
“All antipsychotic drugs (APDs) in use block dopamine (DA) D2 receptors (Carlsson and Lindqvist, 1963; Seeman et al., 1975; Kapur and Remington, 2001), and these drugs are most effective at alleviating the psychotic features of schizophrenia (Seeman, 1992; Kapur and Remington, 2001; Abi-Dargham, 2004; Cincotta and Rode…”
BackgroundSpecific Glial Functions Contribute to Schizophrenia Susceptibility
Goudriaan, A., de Leeuw, C., Ripke, S., Hultman, C. M., Sklar, P., Sullivan, P. F., Smit, A. B., Posthuma, D., & Verheijen, M. H. G. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt109 · Cited by 114
Metadata
- Authors
- Seeman, P., Chau-Wong, M., Tedesco, J., & Wong, K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1975-11
- Volume
- 72
- Issue
- 11
- Pages
- 4376-4380
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2046291435
- Cited by
- 701
- References
- 27
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.